F碱基修饰的血管性血友病因子vWF靶向适配体及其应用
The AF-BT100, a Von von Willebrand factor vWF targeting aptamer modified with F bases, has solved the challenge of early diagnosis and treatment of panvascular diseases, achieving accurate identification of lesions in multiple locations and cardiac protection, and exhibiting excellent imaging and therapeutic effects.
CN121896238BActive Publication Date: 2026-07-17RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 2 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
- Filing Date
- 2026-03-24
- Publication Date
- 2026-07-17
Smart Images
Figure CN121896238B_ABST
Abstract
本发明涉及F碱基修饰的血管性血友病因子vWF靶向适配体及其应用。具体地，本发明提供了一种F碱基修饰的血管性血友病因子（vWF）靶向适配体（AF‑BT100），其包含SEQ ID NO：1所示的核苷酸核心序列，且5'端和3'端各连接有至少两个人工疏水F碱基。本发明还包含放射性核素标记的分子影像探针[68Ga]Ga‑NOTA‑AF‑BT100，可在动脉粥样硬化、颈动脉血栓及急性心肌梗死病灶中实现特异性PET成像。本发明首次实现了基于同一vWF靶向适配体的泛血管疾病诊疗一体化应用，为泛血管疾病的精准诊断与治疗提供了新策略。
Need to check novelty before this filing date? Find Prior Art